| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 408,830 | 380,170 | 184,510 | 246,200 | 345,440 |
| Sales Growth | +7.54% | +106.04% | -25.06% | -28.73% | -17.63% |
| Net Income | 83,720 | 75,090 | -23,890 | 8,930 | 66,810 |
| Net Income Growth | +11.49% | +414.32% | -367.53% | -86.63% | -29.20% |
Hypermarcas ADR (HYPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Hypera S.A. is a pharmaceutical company. It engages in development of pharmaceuticals, dermocosmetics, vitamin supplements, and health products. Hypera serves customers primarily in Latin America. The company was formerly known as Hypermarcas S.A. and is headquartered in Sao Paulo, Brazil.
Fiscal Year End Date: 12/31